A Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety and Tolerability of Zerlasiran in Japanese Subjects With Elevated Serum Lipoprotein(a)

开始日期2024-05-16

申办/合作机构-

NCT05537571

/ Completed临床2期

A Multi-centre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study to Investigate Efficacy, Safety and Tolerability of SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events

Phase 2 study to evaluate the efficacy, safety and tolerability of SLN360 administered subcutaneously (SC) compared with placebo in adult participants with elevated lipoprotein(a) at high risk of atherosclerotic cardiovascular disease events

开始日期2022-12-13

申办/合作机构

Silence Therapeutics Plc

NCT04606602

/ Completed临床1期

A Randomised, Double-blind, Placebo Controlled, First-in-human Study to Investigate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of SLN360 in Subjects With Elevated Lipoprotein(a)

This study will investigate the safety and tolerability of SLN360 in patients with elevated Lp(a).

开始日期2020-11-18

申办/合作机构

Silence Therapeutics Plc

[+1]

100 项与 Zerlasiran 相关的临床结果

登录后查看更多信息

100 项与 Zerlasiran 相关的转化医学

登录后查看更多信息

100 项与 Zerlasiran 相关的专利（医药）

登录后查看更多信息

项与 Zerlasiran 相关的文献（医药）

2025-12-01·Current Atherosclerosis Reports

Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions

Review

作者: Khoja, Adeel ; Inam, Maha ; Murthy, Nikitha ; Epstein, Elizabeth ; Virani, Salim S ; Vaughan, Elizabeth ; Sheikh, Sana ; Mehta, Sandeep ; Minhas, Abdul Mannan Khan ; Slipczuk, Leandro ; Junaid, Vashma ; Chai, Zohar ; Hinkamp, Colin ; Hermel, Melody

PURPOSE OF REVIEW:

Focused review highlighting ten select studies presented at the 2024 American Heart Association (AHA) Scientific Sessions.

RECENT FINDING:

Included studies assessed effects of intensive blood pressure control in patients with type 2 diabetes (BPROAD); decision support system for physicians to optimize early lipid lowering therapies after acute coronary syndrome (ZODIAC); efficacy and safety of zerlasiran, a short interfering RNA targeting lipoprotein(a) (ALPACAR); efficacy and safety of muvalaplin an oral disrupter of the assembly of lipoprotein(a) particles (KRAKEN); safety and efficacy of obicetrapib in patients with heterozygous familial hypercholesterolemia (BROOKLYN); efficacy and safety of lerodalcibep, a third generation PCSK9 inhibitor in heterozygous familial hypercholesterolemia subjects (LIBerate-HeFH_OLE); personalized app-based coaching to improve physical activity in patients with HFpEF compared to standard care (MyoMobile); semaglutide to improve cardiovascular outcomes in patients with a history of coronary artery bypass surgery and overweight or obesity (the SELECT trial); efficacy and safety of plozasiran in adults with genetically or clinically defined familial chylomicronemia syndrome at high risk of acute pancreatitis (PALISADE); and transcriptomic signatures and predictors of evolocumab added to maximum statin therapy based on intra-coronary plaque characteristics (YELLOW III). Research presented at the 2024 AHA Scientific Sessions emphasized innovative strategies in cardiovascular disease prevention and management.

2025-06-01·DIABETES OBESITY & METABOLISM

Comprehensive evaluation of siRNA therapeutics on Lp(a): A network meta‐analysis

Review

作者: Hu, Jiaqiang ; Wang, Xingjin ; Qin, Xiaoli ; Liu, Song ; Zhao, Chen

Abstract:

Aims:

To evaluate the efficacy and safety of siRNA drugs that lower Lp(a) in patients with dyslipidaemia.

Materials and Methods:

A network meta‐analysis and systematic review were conducted to compare siRNA drugs targeting Lp(a), based on relevant randomized controlled trials (RCTs). A comprehensive search was performed in PubMed, Embase, Web of Science and the Cochrane Library (up to October 24, 2024). RCTs with an intervention duration of at least 12 weeks were included. Eligible studies compared siRNA drugs that reduce Lp(a), including both Lp(a)‐targeted and non‐targeted agents, with placebo or other siRNA drugs that reduce Lp(a). The primary outcomes were the percentage reduction and absolute reduction in Lp(a), percentage reduction in low‐density lipoprotein cholesterol (LDL‐C), percentage reduction in apolipoprotein B (apo(B)), adverse events and serious adverse events, including injection‐site reactions. The risk of bias was assessed using the Cochrane Risk of Bias Tool (ROB2), and a random‐effects network meta‐analysis was performed using the frequentist approach. Confidence in effect estimates was evaluated using the Confidence In Network Meta‐Analysis (CINeMA) framework.

Results:

A total of 14 trials involving 5646 participants were included. Lp(a)‐targeted siRNA agents, particularly Olpasiran, demonstrated strong efficacy in significantly reducing Lp(a) levels, with the greatest percentage reduction in Lp(a) (mean difference [MD]: −92.06%; 95% CI: −102.43% to −81.69%; P‐score: 0.98). Olpasiran also showed the greatest absolute reduction in Lp(a) (MD: −250.70 nmol/L; 95% confidence interval [CI]: −279.89 to −221.50; P‐score: 0.99). Certain non‐Lp(a)‐targeted siRNA agents, such as inclisiran and zodasiran, also showed modest reductions in Lp(a) levels, reducing Lp(a) by approximately 15%. Lp(a)‐targeted siRNA agents reduced LDL‐C by more than 20% and decreased apo(B) by approximately 15%. In terms of safety, most drugs exhibited favourable safety profiles with no significant differences compared to placebo. However, zerlasiran raised concerns regarding injection‐site reactions and other adverse events when compared to placebo.

Conclusions:

Lp(a)‐targeted siRNA agents have shown robust effectiveness in substantially reducing Lp(a) levels, including both percentage and absolute reductions, with moderate improvements in LDL‐C and apo(B) concentrations. Non‐Lp(a)‐targeted siRNA agents also demonstrate modest reductions in Lp(a) levels. The safety profile is generally favourable, but zerlasiran and inclisiran may increase the incidence of injection‐site reactions.

2024-12-17·JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a)

Article

作者: Schwartz, Gregory G. ; Ray, Kausik K. ; Rambaran, Curtis ; Troquay, Roland ; Dorresteijn, Jannick A. N. ; Stroes, Erik S. G. ; Nicholls, Stephen J. ; Rider, David A. ; Wang, Qiuqing ; Navar, Ann Marie ; Szarek, Michael ; Fok, Henry ; Wolski, Kathy ; Nissen, Steven E. ; Romano, Steven

Importance:

Elevated lipoprotein(a) increases the risk of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis.

Objective:

To evaluate the effects of zerlasiran, a small-interfering RNA targeting hepatic synthesis of apolipoprotein(a), on lipoprotein(a) serum concentration.

Design, Setting, and Participants:

A multicenter trial in patients with stable ASCVD with serum lipoprotein(a) concentrations greater than or equal to 125 nmol/L at 26 sites in Europe and South Africa between January 3, 2023, and April 27, 2023, with last follow-up on July 1, 2024.

Interventions:

Participants randomized to receive a subcutaneous dose of placebo every 16 weeks for 3 doses (n = 23) or every 24 weeks for 2 doses (n = 24) or zerlasiran 450 mg every 24 weeks for 2 doses (n = 45), 300 mg every 16 weeks for 3 doses (n = 42), or 300 mg every 24 weeks for 2 doses (n = 44).

Main Outcome and Measures:

The primary outcome was the time-averaged percent change in lipoprotein(a) concentration from baseline to 36 weeks, with follow-up to 60 weeks.

Results:

Among 178 patients, mean (SD) age was 63.7 (9.4) years, 46 (25.8%) were female, with a median (IQR) baseline lipoprotein(a) concentration of 213 (177-282) nmol/L; 172 patients completed the trial. Compared with the pooled placebo group, the least-squares mean time-averaged percent change in lipoprotein(a) concentration from baseline to week 36 was −85.6% (95% CI, −90.9% to −80.3%), −82.8% (95% CI, −88.2% to −77.4%), and −81.3% (95% CI, −86.7% to −76.0%) for the 450 mg every 24 weeks, 300 mg every 16 weeks, and 300 mg every 24 weeks groups, respectively. Median (IQR) percent change in lipoprotein(a) concentration at week 36 was −94.5% (−97.3% to −84.2%) for the 450 mg every 24 weeks group, −96.4% (−97.7% to −92.3%) for the 300 mg every 16 weeks group, and −90.0% (−93.7% to −81.3%) for the 300 mg every 24 weeks group. The most common treatment-related adverse effects were injection site reactions, with mild pain occurring in 2.3% to 7.1% of participants in the first day following drug administration. There were 20 serious adverse events in 17 patients, none considered related to the study drug.

Conclusions:

Zerlasiran was well-tolerated and reduced time-averaged lipoprotein(a) concentration by more than 80% during 36 weeks of treatment in patients with ASCVD.

Trial Registration:

ClinicalTrials.gov Identifier: NCT05537571

117

项与 Zerlasiran 相关的新闻（医药）

2025-12-07

·CVDAILY

全球血脂速递（第341期）｜泡沫细胞、多样化、细胞起源、信号通路、脂蛋白(a)、治疗方法

*本资料仅供医疗卫生专业人士参考，请勿向非医疗卫生专业人士发放截至12月07日15点59分，近期共有 216 本期刊发布了 367 篇文章，其中血脂相关的文章共 40 篇，覆盖 9 个领域的内容。中国专家参与发表的文章有 24 篇。今日，影响因子最高的文章刊登在 JACC: Cardiovascular Imaging (IF: 15.200) 期刊上。今日头条 Headlines 01 Scientific reports IF: 03.900 随时间更新的FIB-4指数可预测代谢功能障碍相关脂肪性肝病患者冠状动脉钙化的进展 Lee, Yesung, Lee, Woncheol, etc. 近期，一项发表在《Scientific Reports》上的研究揭示了肝脏健康状况与心脏血管早期病变之间的潜在联系。该研究由Yesung Lee和Woncheol Lee共同完成，探讨了在代谢功能障碍相关脂肪性肝病患者中，一个反映肝纤维化的简单血液指标——FIB-4指数——如何动态预测冠状动脉钙化的进展。冠状动脉钙化是动脉粥样硬化的重要标志，通过冠状动脉CT可以无创检测其钙化积分。而代谢功能障碍相关脂肪性肝病不仅是常见的肝脏疾病，也被认为是一种全身性疾病，可能影响心血管系统。研究人员关注的核心问题是，反映肝脏纤维化程度的FIB-4指数，其随时间的变化能否预警这种早期的心脏血管病变。为了回答这个问题，研究者对2012年至2023年间接受健康检查的超过6万名韩国无症状成年人进行了分析。所有参与者均接受了不止一次的冠状动脉CT扫描和肝脏超声检查。研究团队利用时间依赖性Cox回归模型，评估了反复测量的FIB-4指数与冠状动脉钙化进展风险之间的关系。研究结果发现，在患有代谢功能障碍相关脂肪性肝病的人群中，随时间推移而升高的FIB-4指数，与冠状动脉钙化进展的风险增加存在独立关联。这意味着，即使在考虑了血压、血脂、血糖等传统心血管风险因素后，肝脏纤维化指标的恶化依然预示着冠状动脉钙化的加重。进一步的深入分析显示，这种关联并非均匀存在于所有人群之中。关联性在男性中表现得比女性更为显著。同时，年龄也是一个重要的影响因素，对于年龄在40岁及以上的个体，FIB-4指数与冠状动脉钙化进展的联系更为紧密。综上所述，这项大规模研究提示，在特定人群——尤其是40岁以上的男性代谢功能障碍相关脂肪性肝病患者中，定期监测并评估FIB-4指数的变化，可能有助于识别那些亚临床动脉粥样硬化风险较高的个体。研究者指出，该指标或许可以作为一个方便易得的标志物，反映潜在的亚临床心血管风险。本文由天纳乾坤编辑扫描二维码查看源文 Scientific reports | Ahead of Print. 10.1038/s41598-025-31289-3 02 Nutrition reviews IF: 04.900 8小时限时饮食（16/8 TRE）对成年人糖脂代谢影响的系统综述与荟萃分析 Wong, Po-San, Wan, Kewen, Dai, Zihan, Yu, Angus Pak-Hung, Wong, Stephen Heung-Sang, Poon, Eric Tsz-Chun, etc. 一种将每日进食时间限制在8小时内、并伴随16小时禁食的饮食模式——即16/8限时饮食（TRE），近年来在追求健康的人群中颇为流行。然而，这种饮食方式对血糖和血脂代谢的具体影响，科学证据是否充分？一项最新的系统综述与荟萃分析为此提供了基于现有临床试验的综合答案。该研究由 Wong, Po-San 等人完成，文章发表在 Nutrition reviews 期刊上。研究团队系统检索了截至2025年1月15日的全球主要医学数据库，旨在评估16/8 TRE与常规饮食（对照）相比，对成年人糖脂代谢指标的影响。最终，共23项高质量的随机对照试验被纳入分析，这些研究总计涉及1280名参与者。综合分析结果显示，遵循16/8 TRE的参与者在几个关键的糖代谢指标上表现出轻微的积极变化。具体而言，他们的空腹血糖水平、评估胰岛素抵抗的稳态模型（HOMA-IR）指数以及空腹胰岛素水平，均比遵循对照饮食的参与者有统计学意义上的降低。在脂质谱方面，16/8 TRE主要对高密度脂蛋白胆固醇（HDL-C，常被称为“好”胆固醇）产生了轻微的提升作用。研究未发现16/8 TRE对总胆固醇、低密度脂蛋白胆固醇（LDL-C，“坏”胆固醇）或甘油三酯产生一致的显著影响。然而，进一步深入的亚组分析揭示了更细微的图景。研究效果似乎并非均等地体现在所有人群中。例如，在那些仅招募了男性参与者的研究中，16/8 TRE展现出了更广泛的益处，参与者的甘油三酯和低密度脂蛋白胆固醇水平也得到了显著改善。这表明，饮食干预的代谢反应可能存在性别差异。此外，参与者的生活方式和干预的持久性也扮演着重要角色。分析发现，在参与者基线体力活动水平较高的研究中，低密度脂蛋白胆固醇的降低效果更为明显。同时，当干预持续时间延长至6个月以上时，一个反映长期血糖控制的重要指标——糖化血红蛋白（HbA1c）——也出现了显著的改善。这提示，16/8 TRE对代谢的益处可能需要足够的干预时长和积极的身体活动作为配合才能充分显现。该研究的作者团队总结指出，现有的证据表明，16/8限时饮食模式确实能在整体上带来空腹血糖、胰岛素敏感性及“好”胆固醇水平的轻微改善。但这项荟萃分析也清晰地提示，这种饮食方式的效果并非“一刀切”，其实际收益很可能受到个人性别、日常活动量以及坚持该饮食模式的时间长短等多个因素的共同影响。对于临床实践和公众健康指导而言，这些调节因素值得在推荐个性化营养方案时被充分考虑。本文由天纳乾坤编辑扫描二维码查看源文 Nutrition reviews | Ahead of Print. 10.1093/nutrit/nuaf206 03 J Transl Med IF: 07.500 泡沫细胞：追溯其多样化的细胞起源及相关信号通路 Jiao, Xinyun, Guo, Dachuan, Li, Wenlin, Li, Sainan, Shao, Guangying, Shen, Tao, etc. 近日，一项聚焦于动脉粥样硬化核心病理特征的研究，系统梳理了泡沫细胞这一关键角色的“前世今生”。发表于《Journal of translational medicine》的综述文章“Foam cells: tracing the diverse cellular origins and their linked signaling pathways”明确指出，泡沫细胞在动脉粥样硬化斑块的形成和发展中起着至关重要的作用。这项由Jiao, Xinyun等作者完成的工作，为我们深入理解这一疾病提供了新的视角。长久以来，泡沫细胞被认为主要由血液中的单核细胞分化而来的巨噬细胞转化而成。然而，这篇文章揭示了一个更为复杂的细胞来源图景。研究指出，除了单核细胞，血管壁中的平滑肌细胞也是泡沫细胞的重要前体细胞，在小鼠模型中甚至贡献了超过75%的泡沫细胞，在人类斑块中也占到约一半的比例。此外，树突状细胞、内皮细胞乃至干细胞，都被证实可以转化为泡沫细胞，这大大扩展了我们对其起源的认识。那么，这些细胞是如何转变为充满脂质的泡沫状细胞的呢？文章的核心观点将其归结于细胞内胆固醇代谢稳态的严重失衡。这一过程涉及多个环节的故障：一方面，通过如CD36等清道夫受体进行的脂质过度摄取；另一方面，通过如ABCA1和ABCG1等转运蛋白将胆固醇排出细胞的能力受损。此外，细胞自身的“清洁”系统——自噬功能的缺陷，也阻碍了脂质成分的清除，共同导致了脂质在细胞内的异常蓄积。泡沫细胞的形成并非孤立事件，而是受到体内众多精密信号网络的严密调控。该综述系统总结了参与其中的几条关键通路。首先是以TLR4-NF-κB通路和NLRP3炎症小体为代表的炎症相关通路，它们将免疫反应与脂质代谢紧密相连。其次，以PPARγ-LXRα通路和PI3K/Akt通路为代表的代谢相关通路，直接调控着胆固醇的摄取、合成与外排基因的表达。最后，以Notch通路和Wnt通路为代表的微环境相关通路，则响应细胞周围的信号，影响细胞的分化与功能状态。综上所述，这篇综述清晰地勾勒出泡沫细胞的多元起源和复杂的调控网络。它强调了动脉粥样硬化形成过程中细胞来源的异质性和分子机制的多样性。这一系统性的梳理，不仅深化了学界对疾病根本机制的理解，也为未来开发针对不同细胞来源或特定信号通路的精准治疗策略，提供了潜在的理论依据和干预靶点。本文由天纳乾坤编辑扫描二维码查看源文 J Transl Med | Volume 23, Issue 1 10.1186/s12967-025-07402-5 04 Journal of nanobiotechnology IF: 12.600 超声驱动动脉粥样硬化纳米药物：从力学、空化及声动力疗法到临床应用 Shao, Yusang, Luo, Jiayong, Tu, Shuangshuang, Xie, Yanqing, Zhu, Jinjin, Wu, Aiguo, etc. 动脉粥样硬化是全球心血管疾病死亡的主要原因之一，其斑块不稳定引发的急性心血管事件亟需创新、非侵入性的治疗手段。近年来，超声技术以其独特的优势，成为靶向干预动脉粥样硬化病理机制的一个变革性平台。一篇发表于 Journal of nanobiotechnology 的综述文章，由 Shao, Yusang 等多位学者合作完成，系统梳理了超声技术驱动下的动脉粥样硬化纳米药物疗法。该研究指出，超声主要通过其机械、空化和声动力效应，为治疗动脉粥样硬化提供了三条关键路径。其中，利用超声的热效应和机械效应，可以实现对动脉粥样硬化斑块的直接物理破坏，同时增强治疗性药物的局部递送效率，提升疗效。另一方面，超声在特定条件下引发的空化效应，不仅能够用于物理性的血栓溶解，还能扰动并调节斑块所处的局部微环境，为治疗创造有利条件。更为引人关注的是声动力疗法。该疗法结合超声与特定的声敏剂，能在病变部位产生活性氧。这些高活性的分子可以精准触发斑块内炎症细胞或病变细胞的凋亡或自噬程序，从而从分子层面促进斑块的稳定或消退。文章进一步回顾了相关疗法的临床转化现状。目前，基于超声的溶栓治疗以及声动力疗法治疗动脉粥样硬化，已在临床前研究中展现出显著潜力，部分研究已推进至临床试验阶段，显示出良好的应用前景。尽管前景广阔，该综述也明确指出了当前领域面临的挑战。如何在治疗中平衡超声的能量、频率等参数以确保疗效与安全，如何降低声动力疗法中活性氧可能对正常组织产生的非特异性毒性，以及如何确保所使用的纳米声敏剂具有良好的长期生物安全性，仍是研究者需要攻克的关键科学问题。这篇综述通过深入探讨超声的治疗机制、声敏剂的设计思路以及临床应用进展，旨在为纳米药物领域，特别是心血管疾病精准治疗方向的发展提供有价值的见解与参考。本文由天纳乾坤编辑扫描二维码查看源文 Journal of nanobiotechnology | Volume 23, Issue 1 10.1186/s12951-025-03857-2 05 Expert Opin Pharmacother IF: 02.700 脂蛋白(a)——正在研发中的治疗方法 Tomlinson, Brian, Law, Chak Fun, etc. 近日，一篇发表在《Expert Opinion on Pharmacotherapy》期刊上的综述文章，系统梳理了针对心血管疾病重要风险因子——脂蛋白(a)[Lp(a)]的新型治疗药物的最新研发进展。该文为临床医生和研究者提供了关于这一新兴治疗领域的关键信息。脂蛋白(a)已被证实是动脉粥样硬化性心血管疾病和主动脉瓣狭窄的独立风险因素，其血液水平主要由遗传决定。然而，一个长期困扰临床的难题是，目前广泛应用的降脂药物，如他汀类药物，对降低升高的Lp(a)水平效果甚微。因此，开发能够特异且显著降低Lp(a)的新型疗法，成为了心血管疾病预防和治疗中一个迫切且重要的方向。该综述重点介绍了几类已进入高级研发阶段的新型药物。其中最引人注目的是基于核酸技术的药物，包括N-乙酰半乳糖胺缀合的反义寡核苷酸(ASO) Pelacarsen，以及小干扰RNA(siRNA)药物Olpasiran、Lepodisiran和Zerlasiran。临床研究数据显示，这些药物能够安全且强效地降低Lp(a)水平，降幅可达80%至接近100%，展现出了改变临床实践的潜力。除了注射给药的核酸类药物，一种名为**Muvalaplin**的口服小分子药物也崭露头角。该药物每日服用一次，在研究中能将Lp(a)水平降低高达65%，为患者提供了另一种潜在的治疗选择。这些药物的出现，标志着Lp(a)靶向治疗从理论走向现实。目前，这些新型疗法的价值正在通过更大型的临床试验进行验证。其中，**Pelacarsen**、**Olpasiran**和**Lepodisiran**均已进入旨在评估其对患者心血管硬终点（如心肌梗死、卒中）影响的III期临床研究阶段。**Muvalaplin**的相关心血管结局研究也在进行中。这些试验的结果，预计将在2026年之后陆续揭晓，届时将能更清晰地判断降低Lp(a)是否能为患者带来明确的心血管获益。尽管前景令人鼓舞，文章也指出，未来仍有几个关键的科学问题有待解答。这包括：需要治疗的血浆Lp(a)基线水平阈值是多少？将Lp(a)降低到何种程度能够产生最佳的临床效益？此外，将Lp(a)水平进行接近完全的、大幅度的降低，其长期安全性如何，是否会产生未知的不良反应？这些问题的答案，对于未来制定精准的Lp(a)管理策略至关重要。总而言之，针对Lp(a)的新型靶向疗法研发正处于快速发展阶段，多种药物已在早期临床试验中显示出卓越的降脂效能。随着多项关键性心血管结局临床试验的推进，我们正站在一个可能改写高风险患者管理策略的十字路口。医学界正密切关注着这些研究的进展，期待为降低由Lp(a)升高带来的心血管疾病负担找到新的有力武器。本文由李小慧编辑扫描二维码查看源文 Expert Opin Pharmacother | Ahead of Print. 10.1080/14656566.2025.2601062 中国发表（24） China Food research international IF: 08.000Volume 223, Issue Pt 1No.01Characterization and lipidomics of extracellular vesicles derived from infant formula during storage: Insights from flavor deterioration婴儿配方奶粉储存期间细胞外囊泡的特征与脂质组学研究：风味劣化的新视角DOI: 10.1016/j.foodres.2025.117937 Food research international IF: 08.000Volume 223, Issue Pt 1No.02Effect of oil-soluble emulsifiers on the self-assembly behaviors of citric acid esters in bulk and emulsified systems油溶性乳化剂对柠檬酸酯在整体和乳化体系中自组装行为的影响DOI: 10.1016/j.foodres.2025.117896 Journal of affective disorders IF: 04.900Ahead of Print.No.03Triglyceride glucose-a body shape index (TyG-ABSI) as a potential indicator for cognitive impairment: Results from two nationally representative cohort studies甘油三酯葡萄糖-体形指数 (TyG-ABSI) 作为认知障碍的潜在指标：来自两项全国代表性队列研究的结果DOI: 10.1016/j.jad.2025.120809 Food chemistry IF: 09.800Ahead of Print.No.04Lipidomics-based evaluation of gender and monthly age on the quality of Congling Tibetan chicken基于脂质组学的性别与月龄对藏鸡品质的评价DOI: 10.1016/j.foodchem.2025.147386 Journal of controlled release IF: 11.500Ahead of Print.No.05Design of biomimetic chylomicrons based on 1,3-diolein grafted hyaluronic acid to drive biomacromolecules across the intestinal mucosal barrier基于1,3-二油酸甘油酯接枝透明质酸的仿生乳糜微粒设计用于驱动生物大分子跨越肠道黏膜屏障DOI: 10.1016/j.jconrel.2025.114504 European journal of radiology IF: 03.300Ahead of Print.No.06Personalized adrenal gland volume reference ranges and development of a fully automated deep learning screening tool个性化肾上腺体积参考值范围及全自动深度学习筛查工具的开发DOI: 10.1016/j.ejrad.2025.112591 BMC public health IF: 03.600Ahead of Print.No.07Weight-adjusted waist index outperforms other obesity indices for cardiovascular disease prediction in cardiovascular-kidney-metabolic syndrome: insights from UK biobank体重调整腰围指数在心肾代谢综合征人群中的心血管疾病预测能力优于其他肥胖指标：来自英国生物样本库的启示DOI: 10.1186/s12889-025-25830-2 Life sciences IF: 05.100Ahead of Print.No.08MEGF8-mediated GDF8 phosphorylation drives TGF-β hyperactivation in osteoarthritis cartilage degeneration: Mechanism and targeted interventionMEGF8介导的GDF8磷酸化驱动骨关节炎软骨退变中TGF-β超活化：机制与靶向干预DOI: 10.1016/j.lfs.2025.124139 BMC medical genomics IF: 02.000Ahead of Print.No.09The rs34416841 polymorphism in the Alu element of the circSirt1 flanking intron is associated with an increased risk of myocardial infarction位于环状Sirt1旁侧内含子Alu元件中的rs34416841多态性与心肌梗死风险增加相关DOI: 10.1186/s12920-025-02291-5 Analytica chimica acta IF: 06.000Volume 1383, Issue No.10Fluorescent light-up probes for legumain imaging in macrophages: Minimal disturbance to macrophage cytoskeleton用于巨噬细胞中legumain成像的荧光开启型探针：对巨噬细胞骨架干扰极小DOI: 10.1016/j.aca.2025.344861 Food research international IF: 08.000Volume 223, Issue Pt 1No.11Low-cholesterol egg yolk lipids alleviated the development of atherosclerosis in ApoE (-/-) mice by regulating bile acid metabolism and gut microbiota低胆固醇蛋黄脂质通过调节胆汁酸代谢和肠道菌群缓解ApoE(-/-)小鼠动脉粥样硬化发展DOI: 10.1016/j.foodres.2025.117906 Life sciences IF: 05.100Ahead of Print.No.12The PRMT-mediated arginine methylation: From molecular mechanisms to therapeutic targets in cardiovascular diseasesPRMT介导的精氨酸甲基化：从分子机制到心血管疾病的治疗靶点DOI: 10.1016/j.lfs.2025.124140 International immunopharmacology IF: 04.700Ahead of Print.No.13ACAT1 inhibitor Avasimibe suppresses osteoclastogenesis and alleviates ovariectomy-induced bone loss via CKB/PI3K-AKT signalingACAT1抑制剂Avasimibe通过CKB/PI3K-AKT信号通路抑制破骨细胞生成并缓解卵巢切除术诱导的骨丢失DOI: 10.1016/j.intimp.2025.115973 International immunopharmacology IF: 04.700Ahead of Print.No.14Endoplasmic reticulum stress orchestrates cGAS-STING activation in lipid metabolism-associated disorders内质网应激调控cGAS-STING激活在脂代谢相关疾病中的作用DOI: 10.1016/j.intimp.2025.115968 BMC oral health IF: 03.100Ahead of Print.No.15The association between tooth loss and serum cholesterol levels in adults: a scoping review成人牙齿缺失与血清胆固醇水平的关联：一项范围综述DOI: 10.1186/s12903-025-07431-y Int J Biol Macromol IF: 08.500Ahead of Print.No.16Antioxidant, hypoglycemic and hypolipidemic activities of pectins from Citrus aurantium 'Changshanhuyou'常山胡柚果胶的抗氧化、降血糖和降血脂活性DOI: 10.1016/j.ijbiomac.2025.149501 Nutrition reviews IF: 04.900Ahead of Print.No.17Effect of 8-Hour Time-Restricted Eating (16/8 TRE) on Glucose Metabolism and Lipid Profile in Adults: A Systematic Review and Meta-Analysis8小时限时饮食（16/8 TRE）对成年人糖脂代谢影响的系统综述与荟萃分析DOI: 10.1093/nutrit/nuaf206 Food & function IF: 05.400Ahead of Print.No.18Flax lignan-fortified nanoemulsions potentiate the conversion of α-linolenic acid to n-3 LCPUFAs: cumulative metabolic patterns in non-fasting mice亚麻木脂素强化的纳米乳剂增强α-亚麻酸向n-3 LCPUFAs的转化：非禁食小鼠的累积代谢模式DOI: 10.1039/d5fo03469h J Transl Med IF: 07.500Volume 23, Issue 1No.19Foam cells: tracing the diverse cellular origins and their linked signaling pathways泡沫细胞：追溯其多样化的细胞起源及相关信号通路DOI: 10.1186/s12967-025-07402-5 Journal of nanobiotechnology IF: 12.600Volume 23, Issue 1No.20Ultrasound-driven atherosclerosis nanomedicine: from mechanical, cavitation, and sonodynamic therapies to bedside translation超声驱动动脉粥样硬化纳米药物：从力学、空化及声动力疗法到临床应用DOI: 10.1186/s12951-025-03857-2 Revista de neurología IF: 00.800Volume 80, Issue 10No.21Association Between Atherogenic Index of Plasma and Patients With Acute Ischemic Stroke Receiving Intravenous Thrombolysis: A Retrospective Cohort, Multi-Center Study血浆致动脉粥样硬化指数与接受静脉溶栓治疗的急性缺血性卒中患者的关联：一项多中心回顾性队列研究DOI: 10.31083/RN40923 Expert Opin Pharmacother IF: 02.700Ahead of Print.No.22Lipoprotein(a) - treatments in development脂蛋白(a)——正在研发中的治疗方法DOI: 10.1080/14656566.2025.2601062 CHE IF: 03.500Volume 47, Issue 1No.23Hypertension and Alzheimer's disease: Pathological interplay, comorbidity risks, and new strategies for synergistic management高血压与阿尔茨海默病：病理关联、共病风险及协同管理新策略DOI: 10.1080/10641963.2025.2595154 Eur J Med Res IF: 03.400Volume 30, Issue 1No.24Association between the serum uric acid-to-high-density lipoprotein cholesterol ratio and microalbuminuria in individuals with type 2 diabetes mellitus2型糖尿病患者血清尿酸与高密度脂蛋白胆固醇比值和微量白蛋白尿的相关性DOI: 10.1186/s40001-025-03465-8 其他发布内容（15） More Published Articles Coronary Artery Disease IF: 02.000Volume 37, Issue 1No.01Association between pulse wave velocity and coronary atherosclerosis脉搏波速度与冠状动脉粥样硬化之间的关联DOI: 10.1097/MCA.0000000000001548 Journal of renal nutrition : IF: 03.200Ahead of Print.No.02The Impact of a Major Earthquake on Nutritional Status and Survival in Hemodialysis Patients: A Retrospective Observational Study重大地震对血液透析患者营养状况及生存率的影响：一项回顾性观察性研究DOI: 10.1053/j.jrn.2025.09.005 European journal of pharmacology IF: 04.700Ahead of Print.No.03Uncovering the pleiotropic effects of oleoylethanolamide on obesity-driven chronic kidney disease in mice揭示油酰乙醇胺对肥胖驱动的小鼠慢性肾脏病的多效性作用DOI: 10.1016/j.ejphar.2025.178436 Actas dermo-sifiliográficas IF: 02.800Ahead of Print.No.04Mortality outcomes in patients with plaque psoriasis and hidradenitis suppurativa: the role of biologic therapy斑块状银屑病与化脓性汗腺炎患者的死亡率：生物制剂治疗的作用DOI: 10.1016/j.ad.2025.104525 Environ Toxicol Pharmacol IF: 04.200Ahead of Print.No.05CROTONALDEHDE ORAL EXPOSURE DISRUPT CARDIAC ENERGY METABOLISM AND INDUCES OXIDATIVE STRESS VIA DOWN-REGULATION OF NRF-2 AND UP-REGULATION OF PPARα巴豆醛经口暴露通过下调NRF-2和上调PPARα破坏心脏能量代谢并诱导氧化应激DOI: 10.1016/j.etap.2025.104892 Urology IF: 02.000Ahead of Print.No.06"Editorial Comment on "Erectile Dysfunction as a Predictor of Subclinical Atherosclerosis: A Community Health Assessment Using Coronary Calcium Scoring in Underserved Cleveland, Ohio."编辑评论：《Erectile Dysfunction as a Predictor of Subclinical Atherosclerosis: A Community Health Assessment Using Coronary Calcium Scoring in Underserved Cleveland, Ohio.》DOI: 10.1016/j.urology.2025.11.252 Heart, Lung and Circulation IF: 02.200Ahead of Print.No.07Attainment of Low-Density Lipoprotein Cholesterol Goals and Statin Use in Patients With Atherosclerotic Cardiovascular Disease in Australian General Practice: Are We Doing Enough?澳大利亚全科实践中动脉粥样硬化性心血管疾病患者低密度脂蛋白胆固醇目标达标率与他汀类药物使用：我们做得足够好吗？DOI: 10.1016/j.hlc.2025.07.012 Clinica chimica acta IF: 02.900Ahead of Print.No.08Matrix commutability for ApoA1, ApoB, and lipoprotein(a) testing: Comparison between serum and heparinized plasmaApoA1、ApoB与lipoprotein(a)检测基质可交换性：血清和肝素化血浆对比DOI: 10.1016/j.cca.2025.120748 JACC: Case reportsAhead of Print.No.09Advanced Hybrid Coronary Revascularization With Bilateral Internal Mammary Arteries: Preventing and Managing Left-Sided Cardiac Luxation使用双侧乳内动脉的高级杂交冠状动脉血运重建：左侧心脏脱位的预防与处理DOI: 10.1016/j.jaccas.2025.105843 Curr Med Res Opin IF: 02.200Ahead of Print.No.10Sustained weight reduction with once-weekly semaglutide: results from a real-world retrospective cohort study in the United States (SCOPE 24 months)每周一次司美格鲁肽实现持续减重：美国真实世界回顾性队列研究结果（SCOPE研究24个月）DOI: 10.1080/03007995.2025.2591464 JACC: Cardiovascular Imaging IF: 15.200Ahead of Print.No.11Coronary Inflammatory Risk: A New Therapeutic Target in HIV?冠状动脉炎症风险：HIV治疗的新靶点DOI: 10.1016/j.jcmg.2025.11.003 BMC health services research IF: 03.000Ahead of Print.No.12Understanding community health workers' readiness to provide hyperlipidemia-related self-management support in rural Nepal: a biphasic mixed-methods evaluation评估尼泊尔农村社区健康工作者提供高脂血症相关自我管理支持的准备度：一项双阶段混合方法评价DOI: 10.1186/s12913-025-13834-y HGG Adv IF: 03.600Ahead of Print.No.13Epigenome-wide association study meta-analysis of BMI in African Americans非裔美国人体重指数表观基因组关联研究的荟萃分析DOI: 10.1016/j.xhgg.2025.100552 BMC health services research IF: 03.000Volume 25, Issue 1No.14Trend and quality of care for diabetic patients in diabetes outpatient clinics before and during the COVID-19 pandemicCOVID-19疫情前后糖尿病门诊患者护理趋势与质量的变化DOI: 10.1186/s12913-025-13511-0 Cellular and molecular biology IF: 01.500Volume 71, Issue 11No.15Molecular and cellular biomarkers in Crohn's disease: from pathogenesis to clinical application克罗恩病的分子与细胞生物标志物：从发病机制到临床应用DOI: 10.14715/cmb/2025.71.11.14 16 Atherosclerosis(AS) 动脉粥样硬化 16 Triglycerides(TG) 甘油三酯 3 Hyperlipidemias 高脂血症 2 Lipoprotein(a)(Lp(a)) 脂蛋白a 2 High Density Lipoprotein Cholesterol(HDL-C) 高密度脂蛋白胆固醇 2 Hypercholesterolemia 高胆固醇血症 2 Total Cholesterol(TC) 总胆固醇 1 Statins 他汀 1 Lomitapide 洛美他派编辑：李小慧审校：李小慧

临床结果临床研究

2025-12-07

·心关注

全球血脂速递（第341期）丨动脉粥样硬化、脂蛋白(a)

*本资料仅供医疗卫生专业人士参考，请勿向非医疗卫生专业人士发放截至12月07日15点59分，近期共有 216 本期刊发布了 367 篇文章，其中血脂相关的文章共 40 篇，覆盖 9 个领域的内容。中国专家参与发表的文章有 24 篇。今日，影响因子最高的文章刊登在 JACC: Cardiovascular Imaging (IF: 15.200) 期刊上。今日头条 Headlines 01J Transl Med IF: 07.500泡沫细胞：追溯其多样化的细胞起源及相关信号通路 Jiao, Xinyun, Guo, Dachuan, Li, Wenlin, Li, Sainan, Shao, Guangying, Shen, Tao, etc. 近日，一项聚焦于动脉粥样硬化核心病理特征的研究，系统梳理了泡沫细胞这一关键角色的“前世今生”。发表于Journal of translational medicine的综述文章“Foam cells: tracing the diverse cellular origins and their linked signaling pathways”明确指出，泡沫细胞在动脉粥样硬化斑块的形成和发展中起着至关重要的作用。这项由Jiao, Xinyun等作者完成的工作，为我们深入理解这一疾病提供了新的视角。长久以来，泡沫细胞被认为主要由血液中的单核细胞分化而来的巨噬细胞转化而成。然而，这篇文章揭示了一个更为复杂的细胞来源图景。研究指出，除了单核细胞，血管壁中的平滑肌细胞也是泡沫细胞的重要前体细胞，在小鼠模型中甚至贡献了超过75%的泡沫细胞，在人类斑块中也占到约一半的比例。此外，树突状细胞、内皮细胞乃至干细胞，都被证实可以转化为泡沫细胞，这大大扩展了我们对其起源的认识。那么，这些细胞是如何转变为充满脂质的泡沫状细胞的呢？文章的核心观点将其归结于细胞内胆固醇代谢稳态的严重失衡。这一过程涉及多个环节的故障：一方面，通过如CD36等清道夫受体进行的脂质过度摄取；另一方面，通过如ABCA1和ABCG1等转运蛋白将胆固醇排出细胞的能力受损。此外，细胞自身的“清洁”系统——自噬功能的缺陷，也阻碍了脂质成分的清除，共同导致了脂质在细胞内的异常蓄积。泡沫细胞的形成并非孤立事件，而是受到体内众多精密信号网络的严密调控。该综述系统总结了参与其中的几条关键通路。首先是以TLR4-NF-κB通路和NLRP3炎症小体为代表的炎症相关通路，它们将免疫反应与脂质代谢紧密相连。其次，以PPARγ-LXRα通路和PI3K/Akt通路为代表的代谢相关通路，直接调控着胆固醇的摄取、合成与外排基因的表达。最后，以Notch通路和Wnt通路为代表的微环境相关通路，则响应细胞周围的信号，影响细胞的分化与功能状态。综上所述，这篇综述清晰地勾勒出泡沫细胞的多元起源和复杂的调控网络。它强调了动脉粥样硬化形成过程中细胞来源的异质性和分子机制的多样性。这一系统性的梳理，不仅深化了学界对疾病根本机制的理解，也为未来开发针对不同细胞来源或特定信号通路的精准治疗策略，提供了潜在的理论依据和干预靶点。本文由天纳乾坤编辑扫描二维码查看源文 J Transl Med | Volume 23, Issue 1 10.1186/s12967-025-07402-5 02Expert Opin Pharmacother IF: 02.700脂蛋白(a)——正在研发中的治疗方法 Tomlinson, Brian, Law, Chak Fun, etc. 近日，一篇发表在Expert Opinion on Pharmacotherapy期刊上的综述文章，系统梳理了针对心血管疾病重要风险因子——脂蛋白(a)[Lp(a)]的新型治疗药物的最新研发进展。该文为临床医生和研究者提供了关于这一新兴治疗领域的关键信息。脂蛋白(a)已被证实是动脉粥样硬化性心血管疾病和主动脉瓣狭窄的独立风险因素，其血液水平主要由遗传决定。然而，一个长期困扰临床的难题是，目前广泛应用的降脂药物，如他汀类药物，对降低升高的Lp(a)水平效果甚微。因此，开发能够特异且显著降低Lp(a)的新型疗法，成为了心血管疾病预防和治疗中一个迫切且重要的方向。该综述重点介绍了几类已进入高级研发阶段的新型药物。其中最引人注目的是基于核酸技术的药物，包括N-乙酰半乳糖胺缀合的反义寡核苷酸(ASO) Pelacarsen，以及小干扰RNA(siRNA)药物Olpasiran、Lepodisiran和Zerlasiran。临床研究数据显示，这些药物能够安全且强效地降低Lp(a)水平，降幅可达80%至接近100%，展现出了改变临床实践的潜力。除了注射给药的核酸类药物，一种名为**Muvalaplin**的口服小分子药物也崭露头角。该药物每日服用一次，在研究中能将Lp(a)水平降低高达65%，为患者提供了另一种潜在的治疗选择。这些药物的出现，标志着Lp(a)靶向治疗从理论走向现实。目前，这些新型疗法的价值正在通过更大型的临床试验进行验证。其中，**Pelacarsen**、**Olpasiran**和**Lepodisiran**均已进入旨在评估其对患者心血管硬终点（如心肌梗死、卒中）影响的III期临床研究阶段。**Muvalaplin**的相关心血管结局研究也在进行中。这些试验的结果，预计将在2026年之后陆续揭晓，届时将能更清晰地判断降低Lp(a)是否能为患者带来明确的心血管获益。尽管前景令人鼓舞，文章也指出，未来仍有几个关键的科学问题有待解答。这包括：需要治疗的血浆Lp(a)基线水平阈值是多少？将Lp(a)降低到何种程度能够产生最佳的临床效益？此外，将Lp(a)水平进行接近完全的、大幅度的降低，其长期安全性如何，是否会产生未知的不良反应？这些问题的答案，对于未来制定精准的Lp(a)管理策略至关重要。总而言之，针对Lp(a)的新型靶向疗法研发正处于快速发展阶段，多种药物已在早期临床试验中显示出卓越的降脂效能。随着多项关键性心血管结局临床试验的推进，我们正站在一个可能改写高风险患者管理策略的十字路口。医学界正密切关注着这些研究的进展，期待为降低由Lp(a)升高带来的心血管疾病负担找到新的有力武器。本文由李小慧编辑扫描二维码查看源文 Expert Opin Pharmacother | Ahead of Print. 10.1080/14656566.2025.2601062 中国发表（24） China Food research international IF: 08.000Volume 223, Issue Pt 1No.01Characterization and lipidomics of extracellular vesicles derived from infant formula during storage: Insights from flavor deterioration婴儿配方奶粉储存期间细胞外囊泡的特征与脂质组学研究：风味劣化的新视角DOI: 10.1016/j.foodres.2025.117937 Food research international IF: 08.000Volume 223, Issue Pt 1No.02Effect of oil-soluble emulsifiers on the self-assembly behaviors of citric acid esters in bulk and emulsified systems油溶性乳化剂对柠檬酸酯在整体和乳化体系中自组装行为的影响DOI: 10.1016/j.foodres.2025.117896 Journal of affective disorders IF: 04.900Ahead of Print.No.03Triglyceride glucose-a body shape index (TyG-ABSI) as a potential indicator for cognitive impairment: Results from two nationally representative cohort studies甘油三酯葡萄糖-体形指数 (TyG-ABSI) 作为认知障碍的潜在指标：来自两项全国代表性队列研究的结果DOI: 10.1016/j.jad.2025.120809 Food chemistry IF: 09.800Ahead of Print.No.04Lipidomics-based evaluation of gender and monthly age on the quality of Congling Tibetan chicken基于脂质组学的性别与月龄对藏鸡品质的评价DOI: 10.1016/j.foodchem.2025.147386 Journal of controlled release IF: 11.500Ahead of Print.No.05Design of biomimetic chylomicrons based on 1,3-diolein grafted hyaluronic acid to drive biomacromolecules across the intestinal mucosal barrier基于1,3-二油酸甘油酯接枝透明质酸的仿生乳糜微粒设计用于驱动生物大分子跨越肠道黏膜屏障DOI: 10.1016/j.jconrel.2025.114504 European journal of radiology IF: 03.300Ahead of Print.No.06Personalized adrenal gland volume reference ranges and development of a fully automated deep learning screening tool个性化肾上腺体积参考值范围及全自动深度学习筛查工具的开发DOI: 10.1016/j.ejrad.2025.112591 BMC public health IF: 03.600Ahead of Print.No.07Weight-adjusted waist index outperforms other obesity indices for cardiovascular disease prediction in cardiovascular-kidney-metabolic syndrome: insights from UK biobank体重调整腰围指数在心肾代谢综合征人群中的心血管疾病预测能力优于其他肥胖指标：来自英国生物样本库的启示DOI: 10.1186/s12889-025-25830-2 Life sciences IF: 05.100Ahead of Print.No.08MEGF8-mediated GDF8 phosphorylation drives TGF-β hyperactivation in osteoarthritis cartilage degeneration: Mechanism and targeted interventionMEGF8介导的GDF8磷酸化驱动骨关节炎软骨退变中TGF-β超活化：机制与靶向干预DOI: 10.1016/j.lfs.2025.124139 BMC medical genomics IF: 02.000Ahead of Print.No.09The rs34416841 polymorphism in the Alu element of the circSirt1 flanking intron is associated with an increased risk of myocardial infarction位于环状Sirt1旁侧内含子Alu元件中的rs34416841多态性与心肌梗死风险增加相关DOI: 10.1186/s12920-025-02291-5 Analytica chimica acta IF: 06.000Volume 1383, Issue No.10Fluorescent light-up probes for legumain imaging in macrophages: Minimal disturbance to macrophage cytoskeleton用于巨噬细胞中legumain成像的荧光开启型探针：对巨噬细胞骨架干扰极小DOI: 10.1016/j.aca.2025.344861 Food research international IF: 08.000Volume 223, Issue Pt 1No.11Low-cholesterol egg yolk lipids alleviated the development of atherosclerosis in ApoE (-/-) mice by regulating bile acid metabolism and gut microbiota低胆固醇蛋黄脂质通过调节胆汁酸代谢和肠道菌群缓解ApoE(-/-)小鼠动脉粥样硬化发展DOI: 10.1016/j.foodres.2025.117906 Life sciences IF: 05.100Ahead of Print.No.12The PRMT-mediated arginine methylation: From molecular mechanisms to therapeutic targets in cardiovascular diseasesPRMT介导的精氨酸甲基化：从分子机制到心血管疾病的治疗靶点DOI: 10.1016/j.lfs.2025.124140 International immunopharmacology IF: 04.700Ahead of Print.No.13ACAT1 inhibitor Avasimibe suppresses osteoclastogenesis and alleviates ovariectomy-induced bone loss via CKB/PI3K-AKT signalingACAT1抑制剂Avasimibe通过CKB/PI3K-AKT信号通路抑制破骨细胞生成并缓解卵巢切除术诱导的骨丢失DOI: 10.1016/j.intimp.2025.115973 International immunopharmacology IF: 04.700Ahead of Print.No.14Endoplasmic reticulum stress orchestrates cGAS-STING activation in lipid metabolism-associated disorders内质网应激调控cGAS-STING激活在脂代谢相关疾病中的作用DOI: 10.1016/j.intimp.2025.115968 BMC oral health IF: 03.100Ahead of Print.No.15The association between tooth loss and serum cholesterol levels in adults: a scoping review成人牙齿缺失与血清胆固醇水平的关联：一项范围综述DOI: 10.1186/s12903-025-07431-y Int J Biol Macromol IF: 08.500Ahead of Print.No.16Antioxidant, hypoglycemic and hypolipidemic activities of pectins from Citrus aurantium 'Changshanhuyou'常山胡柚果胶的抗氧化、降血糖和降血脂活性DOI: 10.1016/j.ijbiomac.2025.149501 Nutrition reviews IF: 04.900Ahead of Print.No.17Effect of 8-Hour Time-Restricted Eating (16/8 TRE) on Glucose Metabolism and Lipid Profile in Adults: A Systematic Review and Meta-Analysis8小时限时饮食（16/8 TRE）对成年人糖脂代谢影响的系统综述与荟萃分析DOI: 10.1093/nutrit/nuaf206 Food & function IF: 05.400Ahead of Print.No.18Flax lignan-fortified nanoemulsions potentiate the conversion of α-linolenic acid to n-3 LCPUFAs: cumulative metabolic patterns in non-fasting mice亚麻木脂素强化的纳米乳剂增强α-亚麻酸向n-3 LCPUFAs的转化：非禁食小鼠的累积代谢模式DOI: 10.1039/d5fo03469h J Transl Med IF: 07.500Volume 23, Issue 1No.19Foam cells: tracing the diverse cellular origins and their linked signaling pathways泡沫细胞：追溯其多样化的细胞起源及相关信号通路DOI: 10.1186/s12967-025-07402-5 Journal of nanobiotechnology IF: 12.600Volume 23, Issue 1No.20Ultrasound-driven atherosclerosis nanomedicine: from mechanical, cavitation, and sonodynamic therapies to bedside translation超声驱动动脉粥样硬化纳米药物：从力学、空化及声动力疗法到临床应用DOI: 10.1186/s12951-025-03857-2 Revista de neurología IF: 00.800Volume 80, Issue 10No.21Association Between Atherogenic Index of Plasma and Patients With Acute Ischemic Stroke Receiving Intravenous Thrombolysis: A Retrospective Cohort, Multi-Center Study血浆致动脉粥样硬化指数与接受静脉溶栓治疗的急性缺血性卒中患者的关联：一项多中心回顾性队列研究DOI: 10.31083/RN40923 Expert Opin Pharmacother IF: 02.700Ahead of Print.No.22Lipoprotein(a) - treatments in development脂蛋白(a)——正在研发中的治疗方法DOI: 10.1080/14656566.2025.2601062 CHE IF: 03.500Volume 47, Issue 1No.23Hypertension and Alzheimer's disease: Pathological interplay, comorbidity risks, and new strategies for synergistic management高血压与阿尔茨海默病：病理关联、共病风险及协同管理新策略DOI: 10.1080/10641963.2025.2595154 Eur J Med Res IF: 03.400Volume 30, Issue 1No.24Association between the serum uric acid-to-high-density lipoprotein cholesterol ratio and microalbuminuria in individuals with type 2 diabetes mellitus2型糖尿病患者血清尿酸与高密度脂蛋白胆固醇比值和微量白蛋白尿的相关性DOI: 10.1186/s40001-025-03465-8 其他发布内容（16） More Published Articles Coronary Artery Disease IF: 02.000Volume 37, Issue 1No.01Association between pulse wave velocity and coronary atherosclerosis脉搏波速度与冠状动脉粥样硬化之间的关联DOI: 10.1097/MCA.0000000000001548 Journal of renal nutrition : IF: 03.200Ahead of Print.No.02The Impact of a Major Earthquake on Nutritional Status and Survival in Hemodialysis Patients: A Retrospective Observational Study重大地震对血液透析患者营养状况及生存率的影响：一项回顾性观察性研究DOI: 10.1053/j.jrn.2025.09.005 European journal of pharmacology IF: 04.700Ahead of Print.No.03Uncovering the pleiotropic effects of oleoylethanolamide on obesity-driven chronic kidney disease in mice揭示油酰乙醇胺对肥胖驱动的小鼠慢性肾脏病的多效性作用DOI: 10.1016/j.ejphar.2025.178436 Actas dermo-sifiliográficas IF: 02.800Ahead of Print.No.04Mortality outcomes in patients with plaque psoriasis and hidradenitis suppurativa: the role of biologic therapy斑块状银屑病与化脓性汗腺炎患者的死亡率：生物制剂治疗的作用DOI: 10.1016/j.ad.2025.104525 Environ Toxicol Pharmacol IF: 04.200Ahead of Print.No.05CROTONALDEHDE ORAL EXPOSURE DISRUPT CARDIAC ENERGY METABOLISM AND INDUCES OXIDATIVE STRESS VIA DOWN-REGULATION OF NRF-2 AND UP-REGULATION OF PPARα巴豆醛经口暴露通过下调NRF-2和上调PPARα破坏心脏能量代谢并诱导氧化应激DOI: 10.1016/j.etap.2025.104892 Scientific reports IF: 03.900Ahead of Print.No.06Time-updated FIB-4 index predicts coronary artery calcification progression in individuals with metabolic dysfunction-associated steatotic liver disease随时间更新的FIB-4指数可预测代谢功能障碍相关脂肪性肝病患者冠状动脉钙化的进展DOI: 10.1038/s41598-025-31289-3 Urology IF: 02.000Ahead of Print.No.07"Editorial Comment on "Erectile Dysfunction as a Predictor of Subclinical Atherosclerosis: A Community Health Assessment Using Coronary Calcium Scoring in Underserved Cleveland, Ohio."编辑评论：《Erectile Dysfunction as a Predictor of Subclinical Atherosclerosis: A Community Health Assessment Using Coronary Calcium Scoring in Underserved Cleveland, Ohio.》DOI: 10.1016/j.urology.2025.11.252 Heart, Lung and Circulation IF: 02.200Ahead of Print.No.08Attainment of Low-Density Lipoprotein Cholesterol Goals and Statin Use in Patients With Atherosclerotic Cardiovascular Disease in Australian General Practice: Are We Doing Enough?澳大利亚全科实践中动脉粥样硬化性心血管疾病患者低密度脂蛋白胆固醇目标达标率与他汀类药物使用：我们做得足够好吗？DOI: 10.1016/j.hlc.2025.07.012 Clinica chimica acta IF: 02.900Ahead of Print.No.09Matrix commutability for ApoA1, ApoB, and lipoprotein(a) testing: Comparison between serum and heparinized plasmaApoA1、ApoB与lipoprotein(a)检测基质可交换性：血清和肝素化血浆对比DOI: 10.1016/j.cca.2025.120748 JACC: Case reportsAhead of Print.No.10Advanced Hybrid Coronary Revascularization With Bilateral Internal Mammary Arteries: Preventing and Managing Left-Sided Cardiac Luxation使用双侧乳内动脉的高级杂交冠状动脉血运重建：左侧心脏脱位的预防与处理DOI: 10.1016/j.jaccas.2025.105843 Curr Med Res Opin IF: 02.200Ahead of Print.No.11Sustained weight reduction with once-weekly semaglutide: results from a real-world retrospective cohort study in the United States (SCOPE 24 months)每周一次司美格鲁肽实现持续减重：美国真实世界回顾性队列研究结果（SCOPE研究24个月）DOI: 10.1080/03007995.2025.2591464 JACC: Cardiovascular Imaging IF: 15.200Ahead of Print.No.12Coronary Inflammatory Risk: A New Therapeutic Target in HIV?冠状动脉炎症风险：HIV治疗的新靶点DOI: 10.1016/j.jcmg.2025.11.003 BMC health services research IF: 03.000Ahead of Print.No.13Understanding community health workers' readiness to provide hyperlipidemia-related self-management support in rural Nepal: a biphasic mixed-methods evaluation评估尼泊尔农村社区健康工作者提供高脂血症相关自我管理支持的准备度：一项双阶段混合方法评价DOI: 10.1186/s12913-025-13834-y HGG Adv IF: 03.600Ahead of Print.No.14Epigenome-wide association study meta-analysis of BMI in African Americans非裔美国人体重指数表观基因组关联研究的荟萃分析DOI: 10.1016/j.xhgg.2025.100552 BMC health services research IF: 03.000Volume 25, Issue 1No.15Trend and quality of care for diabetic patients in diabetes outpatient clinics before and during the COVID-19 pandemicCOVID-19疫情前后糖尿病门诊患者护理趋势与质量的变化DOI: 10.1186/s12913-025-13511-0 Cellular and molecular biology IF: 01.500Volume 71, Issue 11No.16Molecular and cellular biomarkers in Crohn's disease: from pathogenesis to clinical application克罗恩病的分子与细胞生物标志物：从发病机制到临床应用DOI: 10.14715/cmb/2025.71.11.14 16Atherosclerosis(AS)动脉粥样硬化 16Triglycerides(TG)甘油三酯 3Hyperlipidemias高脂血症 2Lipoprotein(a)(Lp(a))脂蛋白a 2High Density Lipoprotein Cholesterol(HDL-C)高密度脂蛋白胆固醇 2Hypercholesterolemia高胆固醇血症 2Total Cholesterol(TC)总胆固醇 1Statins他汀 1Lomitapide洛美他派编辑：李小慧审校：李小慧全球血脂速递 AI赋能实时追踪个性定制科室引领

2025-11-28

·翻译endocrine

EnM|综述：精准降脂新时代，降脂疗法创新突破。

期刊：Endocrinology and Metabolism 影响因子：4.2 标题：Innovative Lipid-Lowering Strategies: RNA-Based, Small Molecule, and Protein-Based Therapies 资料来源见链接。如有不适，请线下就医，本文不作为医疗建议。动脉粥样硬化性心血管疾病(ASCVD)仍是全球发病率和死亡率的主要原因。该综述全面概述了新兴的降脂策略。图1A：多种口服降脂药物对低密度脂蛋白胆固醇（LDL-C）的平均降幅，图1B：逐步联合使用多种口服药物可实现累积性LDL-C降低。表1总结了降脂治疗中小分子抑制剂(包括传统和新型药物)先前关键临床试验传统小分子疗法他汀类药物他汀类药物抑制限速酶HMG-CoA还原酶，减少肝脏胆固醇合成并上调低密度脂蛋白(LDL)受体表达。他汀类药物彻底改变了降脂治疗，仍然是降脂治疗的基石。大量临床结局试验确立了他汀类药物作为基石疗法的地位，显示主要不良心血管事件(MACE，包括心血管死亡、非致命性心肌梗死（MI）、非致命性卒中或冠状动脉血管重建的复合结局)减少了20%至40%。获益呈剂量依赖性，高强度他汀类药物可使LDL-C从基线水平降低>50%。斯堪的纳维亚辛伐他汀生存研究（4S试验）：Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9. 心脏保护研究(HPS)：Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvas-tatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22. 治疗新靶点研究(TNT)：LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352:1425-35. 他汀类用于一级预防的证明:评价瑞舒伐他汀的干预性研究 (JUPITER)：Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207. 尽管取得这些成功，由于他汀不耐受、LDL-C降低不足、TG升高或Lp(a)升高，相当大比例的患者仍处于高风险状态。这一差距推动了具有互补作用机制的其他小分子降脂疗法的发展。依折麦布依折麦布（Ezetimibe）通过抑制Niemann-Pick C1样1(NPC1L1)阻断肠道胆固醇吸收。在急性冠脉综合征后将依折麦布添加到辛伐他汀治疗中，可使LDL-C额外降低约24%，并使MACE显著减少约6%，验证了非他汀类小分子作为有效的附加疗法。贝特类药物贝特类药物通过激活过氧化物酶体增殖物激活受体α(PPARα)(一种上调脂肪酸氧化和脂蛋白脂肪酶(LPL)活性相关基因的核受体)发挥其调节血脂的作用，导致血浆TG降低和高密度脂蛋白胆固醇(HDL-C)适度升高。新一代选择性PPARα调节剂(SPPARMα)，佩玛贝特（Pemafibrate）在降低TG(约45%-50%)和增加HDL-C方面效果显著，与非诺贝特相比，肾脏和肝脏不良事件发生率较低。烟酸临床试验显示没有额外获益，现已很少使用。 ω-3脂肪酸二十碳五烯酸(EPA)是唯一具有心血管获益证据的ω-3制剂。在降低心血管事件与二十碳五烯酸乙酯干预试验(REDUCE-IT)中，4g/天的纯化EPA用于他汀治疗且TG升高的患者，使主要心血管事件减少了25%。新型小分子疗法贝派地酸（Bempedoic acid）贝派地酸是一种肝脏激活的三磷酸腺苷-柠檬酸裂解酶(ACLY)抑制剂，作为单一疗法可降低LDL-C约18%，与依折麦布联合使用时可降低约30%-35%。CLEAR Outcomes试验试验(Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic acid and cardiovascular out-comes in statin-intolerant patients. N Engl J Med 2023;388: 1353-64.)在他汀不耐受患者中证明MACE减少了13%，心肌梗死和血运重建显著减少。 CETP抑制剂 CETP抑制通过减少HDL向载脂蛋白B(apoB)含脂蛋白的胆固醇酯转移，同时提高HDL-C并降低LDL-C。然而，新一代CETP抑制剂obicetrapib在与他汀和依折麦布联合使用时显示出叠加效果，提供了完全口服的三联疗法可能，实现与PCSK9靶向生物制剂相当的LDL-C降低。正在进行的III期临床试验旨在确定这些血脂改善是否会转化为主要心血管事件的减少。口服PCSK9抑制剂口服PCSK9抑制剂，如AZD0780，代表了变革性发展。口服PCSK9抑制剂试验(AZD0780)(PURSUIT)IIb期试验显示，在12周内剂量依赖性LDL-C降低约50%，且耐受性良好。 Koren MJ, Vega RB, Agrawal N, Xu Y, Barbour AM, Yu H, et al. An oral PCSK9 inhibitor for treatment of hypercholes-terolemia: the PURSUIT randomized trial. J Am Coll Cardiol 2025;85:1996-2007. Lp(a)抑制剂莫伐倍林（Muvalaplin）是一种口服小分子，通过破坏apo(a)-apoB相互作用阻止Lp(a)的组装。高Lp(a)中的Muvalaplin II期试验(KRAKEN)II期试验显示，Lp(a)降低高达86%，载脂蛋白B和LDL-C也有次要降低。鉴于升高的Lp(a)是一个独立的危险因素，muvalaplin具有填补重大未满足临床需求的潜力。 BET抑制剂阿帕他隆（Apabetalone）是一种溴结构域和末端外(BET)蛋白抑制剂在合并ASCVD和心力衰竭风险的患者中可能有选择性用途。 MTP抑制剂洛美他派(lomitapide)抑制微粒体甘油三酯转移蛋白(MTP)，阻止含apoB脂蛋白的组装。洛美他派获批用于纯合子家族性高胆固醇血症(HoFH)，通过不依赖LDL受体活性的方式降低LDL-C高达50%，但胃肠道不耐受和肝脏脂肪变性限制了其使用。治疗顺序和临床算法对于二级预防，高强度他汀类药物仍是一线选择。依折麦布是LDL-C残留升高的首选附加药物，其次是贝派地酸。贝派地酸也是他汀不耐受个体的重要考虑因素。口服PCSK9抑制剂一旦获批，考虑到药物依从性，预计将发挥重要作用。单克隆抗体和蛋白质疗法 PCSK9单克隆抗体的发展过程、作用机制和临床试验 PCSK9与肝细胞上的低密度脂蛋白受体(LDL-R)结合，促进其溶酶体降解，从而减少循环LDL-C的肝脏清除。抑制性PCSK9单克隆抗体，如依洛尤单抗(evolocumab)和阿利西尤单抗(alirocumab)，抑制这种相互作用，增强LDL-R循环并促进肝细胞对LDL-C的摄取，最终导致血浆LDL-C水平大幅降低。Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK. The PCSK9 decade. J Lipid Res 2012;53:2515-24. 早期应用在依洛尤单抗治疗急性冠脉综合征患者冠状动脉斑块的高分辨率评估(HUYGENS)研究中，依洛尤单抗用于非ST段抬高心肌梗死患者，在72小时内迅速降低LDL-C 50%。血管内成像显示，52周治疗后纤维帽厚度增加，富含脂质的斑块负担减少。 ANGPTL3抑制和残余胆固醇降低 ANGPTL3是肝脏来源的LPL和内皮脂肪酶抑制剂，调节TG和残余胆固醇代谢。依那西尤单抗（Evinacumab，一种靶向ANGPTL3的完全人源化单克隆抗体)，在降低LDL-C(高达50%)、TRLs和含apoB颗粒方面表现出强大的效果，IDL和LDL清除率显著增加。载脂蛋白A-I中心蛋白质疗法 ApoA-I(是HDL颗粒的主要蛋白质成分)在反向胆固醇转运中起核心作用。各种ApoA-I注射疗法的开发。基于RNA的疗法基于RNA的降脂药物采用两种主要分子策略：ASOs和siRNAs。均利用内源通路减少脂质代谢中涉及的靶蛋白表达。靶向PCSK9的RNA疗法英克司兰（Inclisiran）是一种GalNAc结合的siRNA，靶向肝细胞中的PCSK9 mRNA(图5C)。在3期ORION-9、ORION-10和ORION-11试验中，inclisiran在最大耐受剂量他汀治疗基础上实现了持续约50%的LDL-C降低，给药方案为第0天、第3个月，此后每6个月一次。ORION-3的长期扩展数据显示，4年以上的疗效和安全性得以维持。此外，inclisiran治疗在3期临床试验的汇总分析中使MACE显著降低26%。靶向Lp(a)的RNA疗法 Pelacarsen是一种GalNAc结合的ASO，靶向 LPA mRNA(图5C)。在2期研究中，每月给药在已确诊ASCVD和Lp(a)升高的患者中将Lp(a)水平降低了高达80%。 Lepodisiran是一种在研的超长效GalNAc结合siRNA，靶向LPA mRNA，设计为允许每年一次的给药(图5C)。在2期ALPACA试验中，单次608mg皮下注射lepodisiran在第60天将Lp(a)降低了93.9%，>80%的降低持续近1年。 Zerlasiran是另一种siRNA，抑制肝脏载脂蛋白(a)产生，导致Lp(a)显著降低(图5C)。在评估SLN360在心血管疾病中降低脂蛋白(a)的2期试验(ALPACAR-360)中，ASCVD和Lp(a)升高的患者在60周内实现了>80%的平均降低，耐受性良好，主要是轻度注射部位反应，尽管心血管结局获益仍有待证明。靶向ApoC-III的RNA疗法 olezarsen(一种GalNAc结合的ASO，直接降低肝细胞中的APOC3 mRNA)(图5C)。通过沉默apoC-III产生，olezarsen降低TG水平。早期2期和3期研究显示TG稳健降低(40%-60%)和apoC-III水平(>70%)，同时HDL胆固醇有意义增加。olezarsen的临床前景在家族性乳糜微粒血症综合征（familial chylomicronemia syndrome，FCS）患者中得到证实。另一种ApoC-III靶向疗法plozasiran设计用于沉默肝脏中的APOC3表达(图5C)。在评估严重高甘油三酯血症成人中ARO-APOC3的SHASTA-2(2期试验)中，严重高甘油三酯血症患者接受plozasiran治疗后，TG显著降低近60%，而apoC-III水平下降超过80%。在MUIR试验中，plozasiran在24周时显著降低了混合血脂异常患者的TG水平。在FCS患者中进行的3期PALISADE试验中，plozasiran在10个月时将中位TG水平降低了约80%(25mg)和78%(50mg)，而安慰剂组仅降低17%。靶向ANGPTL3和ApoB-100的RNA疗法 ANGPTL3抑制脂蛋白和内皮脂肪酶，升高血浆TG、LDL-C和HDL-C水平。Zodasiran是一种GalNAc结合的siRNA，靶向肝细胞中的ANGPTL3 mRNA(图5C)。同时解决残余脂质风险的多个组分。在2b期ARCHES-2试验中，混合血脂异常患者TG降低高达60%，广泛的血脂谱显著下降，安全性和耐受性良好。基于RNA的降脂疗法的安全性和耐受性随着骨架化学和靶向递送的进步，基于RNA的降脂疗法的安全性显著改善。最常见的不良事件是注射部位反应，通常轻度且短暂，偶尔出现流感样症状。

临床结果

100 项与 Zerlasiran 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
心血管疾病	临床3期	英国	Silence Therapeutics Plc	-
动脉粥样硬化	临床2期	澳大利亚	Silence Therapeutics Plc	2022-12-13
动脉粥样硬化	临床2期	捷克	Silence Therapeutics Plc	2022-12-13
动脉粥样硬化	临床2期	丹麦	Silence Therapeutics Plc	2022-12-13
动脉粥样硬化	临床2期	荷兰	Silence Therapeutics Plc	2022-12-13
动脉粥样硬化	临床2期	斯洛伐克	Silence Therapeutics Plc	2022-12-13
动脉粥样硬化	临床2期	南非	Silence Therapeutics Plc	2022-12-13
动脉粥样硬化	临床2期	英国	Silence Therapeutics Plc	2022-12-13
高脂蛋白血症	临床1期	美国	Medpace, Inc.	2020-11-18
高脂蛋白血症	临床1期	美国	Silence Therapeutics Plc	2020-11-18

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05537571 (ALPACAR-360, CTgov)	临床2期	动脉粥样硬化	180	SLN360 (SLN360 300 mg Q16W)	遞選膚築遞廠遞衊網築(觸網壓鑰艱醖餘獵窪鏇) = 願築廠選窪淵蓋網壓憲構廠淵糧膚遞構鬱廠蓋 (構鑰遞選鏇餘齋窪齋蓋, 1.99) 更多	-	2025-07-01
				SLN360 (SLN360 300 mg Q24W)	遞選膚築遞廠遞衊網築(觸網壓鑰艱醖餘獵窪鏇) = 醖窪網鏇鑰壓襯範廠構構廠淵糧膚遞構鬱廠蓋 (構鑰遞選鏇餘齋窪齋蓋, 1.94) 更多
NCT05537571 (Literature) 人工标引	临床2期	动脉粥样硬化 lipoprotein(a) concentration	178	Zerlasiran 450 mg every 24 weeks for 2 doses	鏇糧獵選艱鬱鏇夢鹹糧(鬱鏇壓壓艱鬱選艱鹹膚) = 淵膚簾鑰簾構襯顧窪構構淵鹽齋築憲齋鏇糧衊 (衊觸顧鏇憲鬱襯願憲齋, −90.9 ~ −80.3) 更多	积极	2024-11-18
				Zerlasiran 300 mg every 16 weeks for 3 doses	鏇糧獵選艱鬱鏇夢鹹糧(鬱鏇壓壓艱鬱選艱鹹膚) = 鬱膚遞積廠餘築窪製淵構淵鹽齋築憲齋鏇糧衊 (衊觸顧鏇憲鬱襯願憲齋, −88.2 ~ −77.4) 更多
NCT05537571 (ALPACAR-360, Company_Website) 人工标引	临床2期	高脂蛋白血症	178	Zerlasiran	製簾壓壓夢遞鬱鏇獵顧(淵簾襯醖壓製遞範膚鹹) = 網構願簾餘憲遞鏇觸網膚艱夢廠遞襯鏇膚醖壓 (壓鏇構淵觸糧繭鬱膚鑰 ) 达到	积极	2024-06-20
				Placebo	-
NCT04606602 (Pubmed) 人工标引	临床1期	动脉粥样硬化	-	Zerlasiran 300 mg (a single subcutaneous dose)	襯淵廠願鑰築壓願構襯(膚構選衊餘窪淵鬱艱餘) = There were no serious adverse events. 遞製築餘鹽顧築鹽顧鏇 (鏇蓋壓遞築範憲鹽範鬱 )	积极	2024-04-08
				Zerlasiran 600 mg (a single subcutaneous dose)
NCT05537571 (ALPACAR-360, Corporate Publications) 人工标引	临床2期	心血管疾病	178	zerlasiran	簾繭範積膚壓鹹觸獵構(壓艱鹹夢範製範窪網製) = 廠蓋鬱獵襯願積鏇衊鏇顧遞願醖獵遞簾蓋壓醖 (壓獵廠淵簾廠網鏇衊築 )	积极	2024-03-13
				Placebo	-
NCT04606602 (APOLLO, Biospace) 人工标引	临床1期	高脂蛋白血症 \| 动脉粥样硬化	36	Zerlasiran	簾觸窪積鹽夢廠積鏇繭(製積積鏇蓋鹹夢艱艱網) = 廠選鏇積鹽觸憲餘淵顧窪築築鏇網範選鹽願網 (觸範襯簾淵鹹夢顧餘淵 ) 更多	积极	2023-11-01
				Placebo	-
NCT04606602 (2020-002471-35, Pubmed \| JAMA)	临床1期	Lp(a)	32	Placebo	醖廠衊鑰願鏇淵鬱蓋鏇(獵膚壓繭遞淵願觸廠糧) = One participant experienced 2 serious adverse event episodes: admission to the hospital for headache following SARS-CoV-2 vaccination and later for complications of cholecystitis, both of which were judged to be unrelated to study drug. 壓餘鑰憲艱顧窪艱鹽築 (齋壓淵鏇膚顧網製鹹鏇 )	积极	2022-05-03
				SLN360 30 mg